Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

Authors

Wataru Yusa
Mayu Yunokawa
Hiroki Ikezawa (ORCID: https://orcid.org/0009-0008-3610-3331)
Y. Hirashima
Yohei Otake
Kazuhiro TAKEHARA
Kosei Hasegawa (ORCID: https://orcid.org/0000-0002-1903-7001)
S. Nishio (ORCID: https://orcid.org/0000-0003-2659-5930)
Koji Matsumoto (ORCID: https://orcid.org/0000-0002-4425-9829)
Hidenori Kato
Takuma Miura
Kan Yonemori

Institutions

Kurume University (JP)
Shizuoka Cancer Center (JP)
The Cancer Institute Hospital (JP)
Shikoku Cancer Center (JP)
Hyogo Prefectural Cancer Center (JP)
Eisai (Japan) (JP)
Saitama Medical University (JP)

Publication Details

Journal: International Journal of Gynecology & Obstetrics
Published: 2025-12-23
DOI: https://doi.org/10.1002/ijgo.70676
Primary Topic: Ovarian cancer diagnosis and treatment
Type: article
Field-Weighted Citation Impact: 0.00

Funders

AstraZeneca
Eisai
Chugai Pharmaceutical

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

Wataru Yusa, Mayu Yunokawa, Hiroki Ikezawa, Y. Hirashima et al.

Dec 23, 2025

International Journal of Gynecology & Obstetrics

Ovarian cancer diagnosis and treatment

article

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

Wataru Yusa, Mayu Yunokawa, Hiroki Ikezawa, Y. Hirashima, Yohei Otake, Kazuhiro TAKEHARA, Kosei Hasegawa, S. Nishio, Koji Matsumoto, Hidenori Kato, Takuma Miura, Kan Yonemori

December 23, 2025article en

Abstract

No abstract available for this paper.

International Journal of Gynecology & Obstetrics

Kurume University (JP), Shizuoka Cancer Center (JP), The Cancer Institute Hospital (JP), Shikoku Cancer Center (JP), Hyogo Prefectural Cancer Center (JP), Eisai (Japan) (JP), Saitama Medical University (JP)

AstraZeneca, Eisai, Chugai Pharmaceutical

Good health and well-being

Openalex Percentile: Top 28%

Ovarian cancer diagnosis and treatment

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results — Wataru Yusa, Mayu Yunokawa, et al. · International Journal of Gynecology & Obstetrics (2025) | TGRS Research Map | TGRS